Detalles de la búsqueda
1.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Diabetologia
; 63(4): 733-743, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858186
2.
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.
Am J Physiol Renal Physiol
; 319(4): F697-F711, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865013
3.
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Am Heart J
; 222: 183-190, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32105984
4.
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
JAMA
; 324(15): 1522-1531, 2020 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079154
5.
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
J Pharmacol Exp Ther
; 365(3): 664-675, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29643251
6.
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.
Pharmacol Res Perspect
; 8(2): e00579, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314550
7.
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Clin J Am Soc Nephrol
; 16(1): 59-69, 2020 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33328269
8.
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
Clin Pharmacol Drug Dev
; 8(5): 564-575, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30422390
9.
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
AIDS
; 21(4): 467-76, 2007 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-17301565
10.
Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.
AIDS
; 20(7): 1027-30, 2006 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-16603855
11.
Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
AIDS
; 17(3): 321-9, 2003 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-12556685
12.
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
J Womens Health (Larchmt)
; 12(7): 655-66, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-14583106
13.
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.
PLoS One
; 5(1): e8781, 2010 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-20107502
14.
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Antiviral Res
; 84(1): 38-47, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19664662
15.
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.
J Acquir Immune Defic Syndr
; 51(2): 125-9, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19349871
16.
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
J Infect Dis
; 193(1): 27-35, 2006 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16323128
17.
ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.
J Infect Dis
; 194(6): 795-803, 2006 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16941346
18.
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.
Antimicrob Agents Chemother
; 49(9): 3607-15, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16127029
19.
Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.
Virology
; 315(1): 159-73, 2003 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-14592768
20.
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.
J Acquir Immune Defic Syndr
; 33(4): 476-83, 2003 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12869836